News Center

News Center

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Recently, Shengshi Taikang, which focuses on both internal R&D and strategic external collaborations, announced that it has signed an exclusive cooperation and licensing agreement with Yunxuan Pharmaceutical, securing global exclusive rights for the development and commercialization of a preclinical-stage CXCR4 antagonist—a promising compound targeting chemokine receptor type 4.

Time：2020-04-16 17:16

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. is an innovative technology company dedicated to the research and development of antidiabetic drugs. The company’s newly developed phosphate senvogliflozin tablets are a novel DPP-4 inhibitor, boasting high potency and exceptional safety profiles. Notably, the drug was successfully selected twice—in 2012 and 2018—for China’s national key programs focused on the creation of major new medicines during the 12th and 13th Five-Year Plans, respectively. This year, data from a large-scale Phase I clinical trial have demonstrated that, compared to the positive-control drug sitagliptin, Shengshi Taikang’s phosphate senvogliflozin shows promising efficacy and remains safe and reliable for treating type 2 diabetes. Currently, the drug has received official approval from the National Medical Products Administration’s Center for Drug Evaluation, allowing it to skip Phase II clinical trials and proceed directly into Phase III testing.

Time：2019-11-14 17:17

Shengshi Taikang Secures Over 100 Million Yuan in A+ Round Funding Led by Hongtai

Shengshi Taikang Secures Over 100 Million Yuan in A+ Round Funding Led by Hongtai

(Suzhou, China – July 30, 2019) Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. has secured a strategic A+ round of financing totaling over 100 million yuan, led by Hongtai Capital with participation from ABC International. This funding will primarily be used to advance the clinical trials of Shengglitine, a new diabetes treatment, as well as accelerate research progress on other innovative drug projects currently in development. Additionally, the company’s rare disease medications, which have already completed consistency evaluations, are set to launch into the market early next year.

Time：2019-07-30 17:23

Focusing on rare diseases, Shengshi Taikang's new drug development holds promise in bringing hope to patients with multiple sclerosis.

Focusing on rare diseases, Shengshi Taikang's new drug development holds promise in bringing hope to patients with multiple sclerosis.

Today marks the 12th International Rare Disease Day. Recall that in 2014, the globally popular Ice Bucket Challenge sparked widespread public attention toward rare diseases—including conditions like ALS, or "Lou Gehrig's disease." Recently, Shengshi Taikang’s Class 3.1 innovative drug, teriflunomide, has officially launched its consistency evaluation clinical trial, offering a promising new treatment option for multiple sclerosis—a disease with symptoms similar to ALS—and potentially bringing much-needed hope to MS patients across China!

Time：2019-02-28 17:23

Shengshi Taikе Receives Approval and Support for the "13th Five-Year National Major New Drug Development Program"

Shengshi Taikе Receives Approval and Support for the "13th Five-Year National Major New Drug Development Program"

Recently, the Research Center for Pharmaceutical and Health Technology Development under the National Health and Family Planning Commission officially issued the "Notice on 2018 Project Proposals Approved under the Major National Science and Technology Special Project for 'Major New Drug Creation'" to companies that have received project approval support. Shengshi Taikang's project, "Research and Development of ESP-8012, a Novel Antidiabetic Drug Belonging to Class 1 Chemical Entities via Dipeptidyl Peptidase Inhibitor Inhibition," has been approved as part of the national major new drug creation initiative during the 13th Five-Year Plan period. Additionally, the company has already received the first installment of central government financial support earmarked for 2018, marking the successful integration of this project into the nation’s priority pipeline for innovative drug development at the highest level.

Time：2018-12-07 17:26

Shengshi Taikang Nominated for the Finals of the 7th China Innovation and Entrepreneurship Competition in the Biomedical Industry

Shengshi Taikang Nominated for the Finals of the 7th China Innovation and Entrepreneurship Competition in the Biomedical Industry

From November 12 to 15, 2018, the finals of the 7th China Innovation & Entrepreneurship Competition in the Biomedical Industry were held in Guangzhou. This event marked the ultimate showdown among China’s top biomedical innovators, while also establishing a national-level platform in Guangzhou to facilitate resource integration and collaborative growth across the industry. The biomedical sector is often hailed as the "crown jewel" of the latest wave of technological innovation. As the nation embarks on its quest to "capture this treasure," a multi-hundred-billion-dollar emerging industry is rapidly rising, driving the robust expansion of the broader health-care ecosystem. Today, the biomedical industry continues to see a surge in groundbreaking innovations and entrepreneurial ventures, with numerous rising stars in biomedicine emerging from this prestigious competition.

Time：2018-11-14 17:31

Sharing innovations in pharmaceutical formulations—stay ahead of the latest trends in chemical drugs at PharmaCon 2018.

Sharing innovations in pharmaceutical formulations—stay ahead of the latest trends in chemical drugs at PharmaCon 2018.

From November 1 to 2, the two-day PharmaCon 2018, the 4th China International Forum on Chemical Drug R&D, was held in Suzhou. This summit brought together over 300 leading scientists, industry executives, and officials from domestic and international pharmaceutical regulatory agencies, who came together to tackle shared challenges and opportunities faced by global pharmaceutical companies—ranging from policy regulations and R&D technologies to emerging market trends. Participants also exchanged insights into the latest developments and shifting industry dynamics, aiming to inspire fresh perspectives that could guide the sector’s future growth.

Time：2018-11-05 15:48

The major "12th Five-Year Plan" project on innovative drug development successfully concluded.

The major "12th Five-Year Plan" project on innovative drug development successfully concluded.

The New Drug Special Project is a science and technology initiative focused on developing critical national strategic products and achieving significant industrialization goals through integrated, collaborative research efforts within a set timeframe. Implemented from 2008 to 2020, the project follows a phased development strategy—divided into three five-year plans labeled "Lay the Foundation," "Organize and Streamline," and "Make Breakthroughs"—to systematically advance its objectives. The overarching goal of the New Drug Special Project is to independently develop and technologically upgrade a range of drugs targeting 10 major diseases, including malignant tumors, while simultaneously strengthening China’s national drug innovation system. This initiative aims to enhance the country’s core R&D capabilities, accelerate the growth of the pharmaceutical industry, and ultimately drive a transformative shift in China’s pharmaceutical sector—from reliance on generic drug production toward true innovation, and from being a global manufacturing powerhouse to becoming a world leader in pharmaceutical innovation and industry strength.

Time：2018-06-01 08:20

< 1...5678 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地